MARVEL CINEMATIC UNIVERSE: GLOBAL GENOCIDE
MCU GLOBAL GENOCIDE
(Thanos (Death) COVID-19 Vaccines)
(CEO of Pfizer)
Pfizer-BioNtech COVID-19 Vaccine
The Official Story
(CEO of Pfizer, 2019+)
Albert Bourla (born October 21, 1961) is a Greek-American veterinarian and the chairman and chief executive officer of Pfizer, an American pharmaceutical company. He joined the company in 1993 and has held several executive roles across Pfizer’s divisions. Prior to becoming chief executive officer, Bourla served as chief operating officer.
In addition to the boards of Pfizer and the Pfizer Foundation, he serves or has served on the boards of the Biotechnology Innovation Organization, Catalyst, the Partnership for New York City, and the Pharmaceutical Research and Manufacturers of America. Bourla is also a member of The Business Council and the Business Roundtable.
Bourla was motivated by an early love for animals and medicine and is credited with reshaping Pfizer to be a company focused on research and development. He is also credited with helping the development of Improvac, which eradicates boar taint, and for refocusing Pfizer’s vaccine division to focus on Staphylococcus, Clostridioides difficile infection, infant diseases, and the Pfizer–BioNTech COVID-19 vaccine. He opposes government interference in pharmaceutical pricing, which he argues would hamper spending on development of new drugs.
Bourla was awarded the 2022 Genesis Prize for his leadership in the development of the Pfizer–BioNTech COVID-19 vaccine.
From 2010 to 2013, Bourla served as president and general manager of Pfizer’s Established Products Business Unit. There, he built business for the company’s drugs that had recently lost patent exclusivity.
From January 2014 to January 2016, Bourla served as Group President of Pfizer’s Global Vaccines, Oncology, and Consumer Healthcare business, where he led Pfizer’s work on cancer and heart drugs, among others, and helped launch Eliquis, an anticoagulant, and Ibrance, a breast cancer treatment drug.
From February 2016 to December 2017, he was group president of Pfizer Innovative Health. In 2016, during his tenure, Innovative Health’s revenue increased by 11%.
Bourla became Pfizer’s chief operating officer (COO) on January 1, 2018, overseeing the company’s drug development, manufacturing, sales and strategy. Bourla pushed Pfizer employees for the fast development of Covid-19. He restructured Pfizer and spun-off the consumer health care business during his tenure as COO.
He was promoted to chief executive officer in October 2018, effective January 1, 2019, succeeding Ian Read, his mentor.
In February 2019, Bourla was one of seven CEOs in the pharmaceutical industry who participated in a hearing on prescription drug prices in the United States with the United States Senate Committee on Finance.
In April 2019, at the Prix Galien Greece Awards ceremony, he was presented with the award for “Preeminent Greek Leader” of the global pharmaceutical industry by Geoffrey R. Pyatt, United States Ambassador to Greece.
In January 2020, Bourla assumed the additional post of executive chairman, upon the retirement of Ian Read.
In 2020, Bourla pushed Pfizer employees for the fast development of a COVID-19 vaccine in partnership with German company BioNTech, making sure it is safe and effective. He told his team that “financial returns should not drive any decisions” with regards to the vaccine. He took the risk of producing the Pfizer–BioNTech COVID-19 vaccine before approval from the Food and Drug Administration so that it would be ready to ship immediately upon approval. However his strategy of pricing during the pandemic has been called “war profiteering” by former CDC chief Tom Frieden.
In 2020, he was ranked as America’s top CEO in the pharmaceutical industry by Institutional Investor.
NEW WORLD ORDER
The New World Order (NWO) is a conspiracy theory which hypothesizes a secretly emerging totalitarian world government. The common theme in conspiracy theories about a New World Order is that a secretive power elite with a globalist agenda is conspiring to eventually rule the world through an authoritarian world government—which will replace sovereign nation-states—and an all-encompassing propaganda whose ideology hails the establishment of the New World Order as the culmination of history’s progress. Many influential historical and contemporary figures have therefore been alleged to be part of a cabal that operates through many front organizations to orchestrate significant political and financial events, ranging from causing systemic crises to pushing through controversial policies, at both national and international levels, as steps in an ongoing plot to achieve world domination.
(CEO of BioNTech)
Pfizer-BioNtech COVID-19 Vaccine
(CEO of BioNTech, 2008+)
Uğur Şahin (born 19 September 1965) is a German oncologist and immunologist. He is the CEO of BioNTech, which developed one of the major vaccines against COVID-19. His main fields of research are cancer research and immunology.
Şahin’s family, originally from Turkey, moved to Germany when he was four years old. He grew up in Cologne and studied medicine at the University of Cologne, completing a doctoral thesis there in cancer immunotherapy. He initially remained in academia, in patient care as an oncohematology physician and conducting research at university hospitals in Saarland and Zürich. He founded a research group at the University of Mainz in 2000 and became a professor of experimental oncology in 2006.
In 2001, while maintaining his position at the University of Mainz, Şahin began to engage in entrepreneurial activities, co-founding two pharmaceutical companies, in 2001 and 2008, with his partner and spouse Özlem Türeci. The second of these companies, BioNTech, together with Pfizer Inc, developed one of the major vaccines used to fight the COVID-19 pandemic in 2020. As a result of the company’s increase in value, Şahin and Türeci became the first Germans with Turkish roots among Germany’s 100 wealthiest people.
Together with Özlem Türeci and Christoph Huber, Şahin founded the biotechnology company BioNTech, based in Mainz, Germany, in 2008 and serves as its CEO. BioNTech is focused on developing and manufacturing active immunotherapies for a patient-specific approach to the treatment of cancer and other serious diseases. The main focus of his research work is the discovery of mRNA-based drugs for use as individualized cancer immunotherapies, as vaccines against infectious diseases, and as protein replacement therapies for rare diseases. He holds a minority interest in the listed company. Since April 2020, BioNTech has been researching a vaccine for the disease COVID-19 under Şahin and Türeci, who is also a member of the company’s board of directors. Şahin is involved in several patents that he has filed with his company and partners.
Against the background of the debate about the distribution of a potential vaccine, Şahin stated that one key in the fight against COVID-19 is international cooperation and equality of distribution. He said there was “no discussion” about whether a vaccine would be made available exclusively to individual countries. Şahin opposes compulsory vaccination and emphasizes the voluntary nature of the vaccination.
In fall 2020, he entered a partnership with the U.S. pharmaceutical company Pfizer and planned to obtain approval for a vaccine before the end of 2020. In November, the company reported a 95 percent efficacy of the BNT162b2 vaccine.
RNA vaccine against COVID-19
In January 2020, Sahin and his teams pivoted from cancer to COVID-19 vaccine development. The rapid publication of the sequence of SARS-COV-2 enabled them to initiate an RNA vaccine discovery program. The versatile nature of their mRNA technology and the groundwork Sahin’s team had done in the area of cancer vaccines allowed them to develop, produce and test multiple mRNA vaccine candidates in parallel. BNT162b2 was discovered as the best candidate for the particular purpose of vaccinating for COVID19 prevention. BNT162b2 is a lipid nanoparticle encapsulated, nucleoside-modified RNA vaccine encoding SARS-CoV-2 spike protein and combines multiple features for optimized vaccine activity derived from Sahin, Türeci and their teams prior work. Clinical trials and subsequent real-world studies established that BNT162b2 vaccine is very effective in inducing immune responses and proved the safety and potent efficacy in humans. BNT162b2 became the first mRNA drug approved for human use and the fastest vaccine developed against a new pathogen in the history of medicine.
(of a stimulus or mental process) below the threshold of sensation or consciousness; perceived by or affecting someone’s mind without their being aware of it.
MIND CONTROL TRUTH
Global Genocide Foreshadowing:
Avengers: Infinity War (2018)
HOLLYWOOD PREDICTIVE PROGRAMMING
Predictive Programming is the concept whereby conspirators plan a false flag operation, they hide references to it in the popular media before the atrocity takes place; when the event occurs, the public has softened up, and therefore passively accepts it rather than offering resistance or opposition.
A false flag is a covert operation designed to deceive; the deception creates the appearance of a particular party, group, or nation being responsible for some activity, disguising the actual source of responsibility.
PFIZER–BIONTECH COVID-19 VACCINE
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with American company Pfizer to carry out clinical trials, logistics, and manufacturing. It is authorized for use in people aged five years and older in some jurisdictions, twelve years and older in some jurisdictions, and for people sixteen years and older in other jurisdictions, to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) encoding a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial advice indicated that vaccination required two doses given 21 days apart, but the interval was later extended to up to 42 days in the US, and up to four months in Canada.
Clinical trials began in April 2020; by November 2020, the vaccine entered phase III clinical trials, with over 40,000 people participating. An interim analysis of study data showed a potential efficacy of 91.3% in preventing symptomatic infection within seven days of a second dose and no serious safety concerns. Most side effects are mild to moderate in severity and are gone within a few days. The most common include mild to moderate pain at the injection site, fatigue, and headaches. Reports of serious side effects, such as allergic reactions, are very rare and no long-term complications have been reported.
The vaccine is the first COVID 19 vaccine to be authorized by a stringent regulatory authority for emergency use and the first cleared for regular use. In December 2020, the United Kingdom was the first country to authorize its use on an emergency basis. It is authorized for use at some level in the majority of countries. On 23 August 2021, the Pfizer–BioNTech vaccine became the first COVID-19 vaccine to be approved in the United States by the Food and Drug Administration (FDA) for those aged sixteen years and older.
As of September 2021, more than 1.5 billion COVID-19 vaccine doses have been shipped by the company worldwide. As of 30 March 2021, Pfizer and BioNTech aimed to manufacture about 2.5 billion doses in 2021. Distribution and storage is a logistical challenge because the vaccine needs to be stored at extremely low temperatures.
In August 2022, a bivalent version of the vaccine (Pfizer-BioNTech COVID-19 Vaccine, Bivalent) was authorized for use as a booster dose in individuals twelve years of age and older in the United States. In September 2022, the BA.1 version of the bivalent vaccine (Comirnaty Original/Omicron BA.1) was authorized as a booster for use in the United Kingdom for people aged twelve years of age and older. In September 2022, the European Union authorized both the BA.1 and the BA.4/BA.5 booster versions of the bivalent vaccine for people aged twelve years of age and older.
The BioNTech technology for the BNT162b2 vaccine is based on use of nucleoside-modified mRNA (modRNA) which encodes a mutated form of the full-length spike protein found on the surface of the SARS-CoV-2 virus, triggering an immune response against infection by the virus protein.
Although jointly developed with Pfizer, Comirnaty is based on BioNTech’s proprietary mRNA technology, and BioNTech holds the Marketing Authorization in the United States, the European Union, the UK, and Canada; expedited licenses such as the US emergency use authorization (EUA) are held jointly with Pfizer in many countries.
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) gave the vaccine “rapid temporary regulatory approval to address significant public health issues such as a pandemic” on 2 December 2020, which it is permitted to do under the Medicines Act 1968. It is the first COVID 19 vaccine to be approved for national use after undergoing large scale trials, and the first mRNA vaccine to be authorized for use in humans. The United Kingdom thus became the first Western country to approve a COVID 19 vaccine for national use, although the decision to fast-track the vaccine was criticized by some experts.
After the United Kingdom, the following countries and regions expedited processes to approve the Pfizer–BioNTech COVID 19 vaccine for use: Argentina, Australia, Bahrain, Canada, Chile, Costa Rica, Ecuador, Hong Kong, Iraq, Israel, Jordan, Kuwait, Malaysia, Mexico, Oman, Panama, the Philippines, Qatar, Saudi Arabia, Singapore, South Korea, the United Arab Emirates, the United States, and Vietnam.
The World Health Organization (WHO) authorized it for emergency use.
In the United States, an emergency use authorization (EUA) is “a mechanism to facilitate the availability and use of medical countermeasures, including vaccines, during public health emergencies, such as the current COVID 19 pandemic”, according to the Food and Drug Administration (FDA). Pfizer applied for an EUA on 20 November 2020, and the FDA approved the application three weeks later on 11 December 2020. The US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) approved recommendations for vaccination of those aged sixteen years or older. Following the EUA issuance, BioNTech and Pfizer continued the Phase III clinical trial to finalize safety and efficacy data, leading to application for licensure (approval) of the vaccine in the United States. On 10 May 2021, the US FDA also authorized the vaccine for people aged 12 to 15 under an expanded EUA. The FDA recommendation was endorsed by the ACIP and adopted by the CDC on 12 May 2021. In October 2021, the EUA was expanded to include children aged 5 through 11 years of age. In June 2022, the EUA was expanded to include children aged six months through four years of age.
On 16 February 2021, the South African Health Products Regulatory Authority (SAHPRA) in South Africa issued Section 21, Emergency Use Approval for the vaccine.
On 5 May 2021, Health Canada authorized the vaccine for people aged 12 to 15. On 18 May 2021, Singapore’s Health Sciences Authority authorized the vaccine for people aged 12 to 15. The European Medicines Agency (EMA) followed suit on 28 May 2021.
On 4 June 2021, the UK Medicines and Healthcare products Regulatory Agency (MHRA) came to a similar decision and approved the use of the vaccine for people twelve years of age and older.
On 19 December 2020, the Swiss Agency for Therapeutic Products (Swissmedic) granted temporary authorization for the Pfizer–BioNTech COVID 19 vaccine for regular use, two months after receiving the application, saying the vaccine fully complied with the requirements of safety, efficacy and quality. This is the first authorization under a standard procedure.
On 21 December 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting conditional marketing authorization for the Pfizer–BioNTech COVID 19 vaccine under the brand name Comirnaty. The recommendation was accepted by the European Commission the same day.
On 23 February 2021, the Brazilian Health Regulatory Agency approved the Pfizer–BioNTech COVID 19 vaccine under its standard marketing authorization procedure. In June 2021, the approval was extended to those aged twelve or over. Pfizer’s negotiation process with Brazil (and other Latin American countries) was described as “bullying”. The contract prohibits the state of Brazil from publicly discussing the existence or the terms of their agreement with Pfizer–BioNTech without the former’s written consent. Brazil was also restricted from donating or receiving donations of vaccines.
In July 2021, the U.S. Food and Drug Administration (FDA) granted priority review designation for the biologics license application (BLA) for the Pfizer–BioNTech COVID-19 vaccine with a goal date for the decision in January 2022. On 23 August 2021, the FDA approved the vaccine for use for those aged sixteen years and older.
The Pfizer-BioNTech Comirnaty COVID-19 vaccine was authorized in Canada on 16 September 2021, for people aged twelve and older.
In July 2022, the FDA approved the vaccine for use for those aged twelve years and older.
In September 2022, the CHMP of the EMA recommended converting the conditional marketing authorizations of the vaccine into standard marketing authorizations. The recommendation covers all existing and upcoming adapted Comirnaty vaccines, including the recently-approved adapted Comirnaty Original/Omicron BA.1 and Comirnaty Original/Omicron BA.4/5.
PFIZER- BIONTECH COVID-19 VACCINE
NEW WORLD ORDER / GLOBAL GENOCIDE 2025
(Click Links Below)
- Marshall Islands
- New Zealand
- Saudi Arabia
- United States
- Bosnia and Herzegovina
- Cape Verde
- Costa Rica
- Dominican Republic
- East Timor
- El Salvador
- Ivory Coast
- North Macedonia
- Papua New Guinea
- San Marino
- South Africa
- South Korea
- Sri Lanka
- United Arab Emirates
- United Kingdom
- Vatican City
Emergency (EMA countries)
Emergency (CARPHA countries)
- Antigua and Barbuda
- Saint Kitts and Nevis
- St. Lucia
- St. Vincent and the Grenadines
- Trinidad and Tobago
- American Samoa
- British Virgin Islands
- Caribbean Netherlands
- Cayman Islands
- Cook Islands
- Faroe Islands
- French Polynesia
- Hong Kong
- Isle of Man
- New Caledonia
- Northern Cyprus
- Northern Mariana Islands
- Puerto Rico
- Sint Maarten
- Turks and Caicos Islands
- World Health Organization
- Czech Republic
THE SNAP/GENOCIDE TRUTH
COVID-19 Vaccines unleashed in December 2020
Worldwide – Total COVID-19 Statistics
|to January 2021:||to January 2023:|
|Confirmed cases: 83,579,767||Confirmed cases: 660,513,619|
|Deaths: 1,820,923||Deaths (reported): 6,690,459|
Deaths (est.): 16.6–28.3 million
Worldwide – Total COVID-19 vaccination
(to January 1, 2023)
(69.11% of the population)
Click above to view the original archived page